In these works, baicalin was shown to inhibit the PI3K signaling pathway to treat osteosarcoma [45], glaucoma [46], spinal cord injury [47], neuroinflammation [48], and pulmonary hypertension [49]. Here, PIK3CG is linked to pulmonary arterial hypertension.